Enalapril and losartan are more effective than carvedilol in preventing dilated cardiomyopathy in the Syrian cardiomyopathic hamster

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 13, Issue 3, 2008, Pages 199-206

  Crespo, Maria J ^a   Cruz, Nildris ^a   Altieri, Pablo I ^a   Escobales, Nelson ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Cardiac function; Carvedilol; Dilated cardiomyopathy; Enalapril; Heart failure; Losartan; Syrian cardiomyopathic hamsters

Indexed keywords

CARVEDILOL; ENALAPRIL; LOSARTAN;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; MALE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CARBAZOLES; CARDIAC OUTPUT; CARDIOMYOPATHY, DILATED; CRICETINAE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENALAPRIL; LOSARTAN; MALE; MESOCRICETUS; PROPANOLAMINES; RENIN-ANGIOTENSIN SYSTEM; STROKE VOLUME; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 49749142667     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248408320006     Document Type: Article

References (47)

1. McKenzie DB, Cowley AJ Drug therapy in chronic heart failure. Postgrad Med J. 2003 ; 79: 634-642.
2. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2001 ; 38: 2101-2113.
3. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN The neurohumoral axis in congestive heart failure. Ann Intern Med. 1984 ; 101: 370-377.
4. Remme WJ, Swedberg K. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001 ; 22: 1527-1560.
5. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 ; 316: 1429-1435.
6. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 ; 325: 293-302.
7. Cohn JN, Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 ; 325: 303-310.
8. Pitt B., Segal R., Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 1997 ; 349: 747-752.
9. Cohn JN, Tognoni G., Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 ; 345: 1667-1675.
10. MERIT-HF Study Group. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Effect of metoprolol CR/XL in chronic heart failure. Lancet. 1999 ; 353: 2001-2007.
11. Packer M., Fowler MB, Roecker EB, et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002 ; 106: 2194-2199.
12. Neglia D., De Maria R., Masi S., et al. Effects of long-term treatment with carvedilol on myocardial blood flow in idiopathic dilated cardiomyopathy. Heart. 2007 ; 93: 808-813.
13. Poole-Wilson PA, Swedberg K., Cleland JG, et al. Carvedilol or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomized controlled trial. Lancet. 2003 ; 362: 7-13.
14. Cleland JG, Pennell DJ, Ray SG, et al. Carvedilol hibernating reversible ischaemia trial: marker of success investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomized controlled trial. Lancet. 2003 ; 362: 14-21.
15. Fowler MB Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial: carvedilol in severe heart failure. Am J Cardiol. 2004 ; 93: 35B - 39B.
16. Schwarz ER, Kersting PH, Reffelmann T., et al. Cardioprotection by carvedilol: antiapoptosis is independent of β-adrenoceptor blockage in the rat heart. J Cardiovasc Pharmacol Ther. 2003 ; 8: 207-215.
17. Yang Y., Tang Y., Ruan Y., et al. Comparison of metoprolol with low, middle and high doses of carvedilol in prevention of postinfarction left ventricular remodeling in rats. Jpn Heart J. 2003 ; 44: 979-988.
18. Barone FC, Campbell WG Jr, Nelson AH, Feuerstein GZ Carvedilol prevents severe hypertensive cardiomyopathy and remodeling. J Hypertens. 1998 ; 16: 871-884.
19. Tang WH, Francis GS The year in heart failure. J Am Coll Cardiol. 2006 ; 48: 2575-2583.
20. Gertz EW Cardiomyopathic Syrian hamster. A possible model of human disease. Prog Exp Tumor Res. 1972 ; 16: 242-260.
21. Forman R., Parmley WW, Sonneblick EH Myocardial contractility in relation to hypertrophy and failure in myopathic Syrian hamster. J Mol Cell Cardiol. 1972 ; 4: 203-211.
22. Strobeck JE, Factor SM, Bhan A., et al. Hereditary and acquired cardiomyopathies in experimental animals; mechanical, biochemical and structural features. Ann N Y Acad Sci. 1979 ; 317: 59-88.
23. Inoue A., Yamashina S., Yamazaki J. The effect of beta-blocker on hamster model BIO 53.58 with dilated cardiomyopathy determined using 123I-MIBG myocardial scintigraphy. Ann Nucl Med. 2003 ; 17: 677-683.
24. Cruz N., Arocho L., Rosario L., Crespo MJ Chronic administration of carvedilol improves cardiac function of 6-month-old Syrian cardiomyopathic hamsters. Pharmacology. 2007 ; 80: 144-150.
25. Ikeda Y., Martone M., Gu Y., et al. Altered membrane proteins and permeability correlate with cardiac dysfunction in cardiomyopathic hamsters. Am J Physiol Heart Circ Physiol. 2000 ; 278: H1362 - H1370.
26. Paraskevaidis I., Farmakis D., Parissis JT, et al. Carvedilol improves left atrial and left ventricular function and reserve in dilated cardiomyopathy after 1 year of treatment. J Card Fail. 2007 ; 13: 108-113.
27. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation. 1991 ; 84: 2426-2441.
28. Buikema H. Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease. Expert Rev Cardiovasc Ther. 2006 ; 4: 631-647.
29. Barnett A. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial. Am Soc Nephrol. 2006 ; 17 (4 Suppl 2). S132 - S135.
30. Crespo MJ, Altieri PI, Escobales N. Enhanced contractility of Ang II in the aorta of cardiomyopathic hamsters is mediated by an increased Ang II-binding capacity and release of ET-1. Vasc Pharmacol. 2006 ; 44: 247-252.
31. Crespo MJ, De Mello WC Chronic administration of losartan plus hydrochlorothiazide improves vascular status in young cardiomyopathic hamsters. Eur J Pharmacol. 2001 ; 420: 133-141.
32. Crespo MJ, Escobales N., Altieri PI Altered vascular function in early stages of heart failure in hamsters. J Card Fail. 1997 ; 3: 311-318.
33. Crespo MJ Vascular alterations during the development and progression of experimental heart failure. J Card Fail. 1999 ; 5: 55-63.
34. Escobales N., Crespo MJ Angiotensin II-dependent vascular alterations in young cardiomyopathic hamsters: role of oxidative stress. Vasc Pharmacol. 2006 ; 44: 22-28.
35. Dixon IM, Ju H., Reid NL, Scammell-La Fleur T., Werner JP, Jasmin G. Cardiac collagen remodeling in the cardiomyopathic Syrian hamster and the effect of losartan. J Mol Cell Cardiol. 1997 ; 29: 1837-1850.
36. Goineau S., Nisse-Durgeat S., Pape D., Guillo P., Ramée MP, Bellissant E. Systemic and regional hemodynamic and cardiac remodeling effects of candesartan in dilated cardiomyopathic hamsters with advanced congestive heart failure. J Cardiovasc Pharmacol. 2002 ; 40: 189-200.
37. Lanza GM, Scott MJ, Davison G., et al. Angiotensin II receptor blockade in Syrian hamster (T0-2) cardiomyopathy does not affect microscopic cardiac material properties: implications for mechanisms of tissue remodeling. Cardiovasc Drugs Ther. 1997 ; 11: 521-529.
38. Dzau VJ, Ellison KE, Brody T., Ingelfinger J., Pratt RE A comparative study of the distributions of renin and angiotensinogen messenger ribonucleic acids in rat and mouse tissues. Endocrinology. 1997 ; 120: 2334-2338.
39. Urata H., Kinoshita A., Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990 ; 265: 22348-22357.
40. Takai S., Shiota N., Yamamoto D., Okunishi H., Miyazaki M. Purification and characterization of angiotensin IIgenerating chymase from hamster cheek pouch. Life Sci. 1996 ; 58: 591-597.
41. Suzuki H., Kanno Y., Kaneko K., et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial. 2004 ; 8: 320-327.
42. Yasumura Y., Miyatake K., Okamoto H., et al. Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure. Circ J. 2004 ; 68: 361-366.
43. Krum H., Carson P., Farsang C., et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail. 2004 ; 6: 937-945.
44. Yagi S., Morita T., Katayama S. Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res. 2004 ; 27: 129-135.
45. Shimizu T., Okamoto H., Chiba S., et al. Long-term combined therapy with an angiotensin type I receptor blocker and an angiotensin converting enzyme inhibitor prolongs survival in dilated cardiomyopathy. Jpn Heart J. 2002 ; 43: 531-543.
46. Ruffolo RR Jr, Gellai M., Heible JP, Willette RN, Nichols AJ The pharmacology of carvedilol. Eur J Clin Pharmacol. 1990 ; 38 (Suppl 2). 82-88.
47. Yue T.-L., Liu T., Feuerstein G. Carvedilol, a new vasodilator and β-adrenoceptor antagonist, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes. Pharmacol Commun. 1992 ; 1: 27-35.